Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to -$274066.0.

  • InMed Pharmaceuticals' Change in Accured Expenses rose 5733.66% to -$274066.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $118598.0, marking a year-over-year increase of 44251.14%. This contributed to the annual value of -$249728.0 for FY2025, which is 65149.51% down from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Change in Accured Expenses is -$274066.0, which was up 5733.66% from -$5431.0 recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Change in Accured Expenses high stood at $765664.0 for Q4 2021, and its period low was -$642392.0 during Q3 2024.
  • Over the past 5 years, InMed Pharmaceuticals' median Change in Accured Expenses value was -$159260.0 (recorded in 2022), while the average stood at -$123331.8.
  • Per our database at Business Quant, InMed Pharmaceuticals' Change in Accured Expenses tumbled by 25318.6% in 2023 and then soared by 31281.71% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Change in Accured Expenses stood at $765664.0 in 2021, then tumbled by 145.66% to -$349611.0 in 2022, then soared by 169.04% to $241378.0 in 2023, then soared by 48.98% to $359614.0 in 2024, then crashed by 176.21% to -$274066.0 in 2025.
  • Its Change in Accured Expenses was -$274066.0 in Q3 2025, compared to -$5431.0 in Q2 2025 and $38481.0 in Q1 2025.